FDA approves a next-generation Covid vaccine from Moderna, with restrictions

The FDA approved Moderna's new Covid-19 vaccine, mNexspike, but restricted its use to individuals aged 65 and older, and those aged 12-64 with high-risk medical conditions, unlike its existing Spikevax vaccine which is approved for a broader age range. Moderna's CEO stated both vaccines will remain available, with mNexspike offering a refined approach using a smaller dose and generating higher antibody levels, particularly in older adults, according to Phase 3 trial data. However, the approval comes amid skepticism from the Department of Health and Human Services, which recently canceled contracts with Moderna and removed the recommendation for pregnant people to receive Covid vaccines from the CDC's adult vaccine schedule, signaling a shift towards targeted vaccine use for high-risk groups.

Analysis

The Food and Drug Administration's approval of Moderna's new Covid-19 vaccine, mNexspike, represents a product development milestone, offering a refined viral target, a smaller dosage (one-fifth of Spikevax), and reportedly generating higher antibody levels, especially in older adults, according to Phase 3 trial data. However, this approval is significantly tempered by its restricted license, limiting use to individuals aged 65 and older, and those aged 12-64 with specific high-risk medical conditions, a narrower scope than the company's existing Spikevax vaccine. This constrained market access emerges within a challenging political and regulatory landscape for Moderna. Notably, the Department of Health and Human Services (HHS), under Health Secretary Robert F. Kennedy Jr., recently canceled $766 million in contracts with Moderna for influenza vaccine development, with an HHS spokesperson terming mRNA technology "under-tested" and raising vague safety concerns, despite billions of mRNA vaccine doses administered globally since late 2020 with a generally favorable safety profile, barring rare myocarditis cases. This skepticism is further underscored by policy shifts, such as the removal of CDC recommendations for Covid shots for healthy children and pregnant people and FDA leadership commentary questioning the benefits for non-high-risk individuals, signaling a move towards more targeted vaccine deployment. While the FDA met its May 31 decision deadline for mNexspike, contrasting with delays for Novavax, Moderna is required to conduct post-marketing studies, including one on vaccine use during pregnancy, which may prove challenging given the revised CDC guidance.

Key Decisions for Investors

• Investors should interpret mNexspike's approval as a qualified development for Moderna, given that its market potential is substantially limited by stringent usage restrictions and an increasingly cautious U.S. public health policy stance on broad mRNA vaccine deployment.
• Closely monitor future U.S. government pronouncements and policy actions from the FDA, CDC, and HHS concerning mRNA vaccines and COVID-19 vaccination strategies, as these will critically influence the addressable market and future revenue streams for Moderna's COVID-19 products.
• Evaluate the increased risk profile for Moderna (MRNA) due to ongoing regulatory uncertainties, contract cancellations like the $766 million influenza deal, and the shifting public health narrative, which could impact investor sentiment and the company's valuation.